- Liver Fibrosis Tumor Necrosis Factor (TNF) Inhibitors are therapeutic agents designed to block the activity of TNF-α, a pro-inflammatory cytokine implicated in the progression of liver fibrosis. Liver fibrosis occurs when chronic liver injury leads to excessive accumulation of extracellular matrix proteins, eventually impairing liver function and potentially progressing to cirrhosis
- The global liver fibrosis TNF inhibitors market is experiencing notable growth, projected to expand at a CAGR of 11.12% in the coming years. This growth is primarily driven by the rising prevalence of chronic liver diseases such as hepatitis B and C, non-alcoholic steatohepatitis (NASH), and alcohol-induced liver damage. Inflammatory pathways, especially those involving TNF-α, play a crucial role in the fibrogenesis process, making TNF inhibitors an important therapeutic avenue to slow disease progression and improve patient outcomes
- In addition, increasing investments in clinical trials and research for anti-fibrotic therapies are fueling market expansion. Advances in biologics and the development of biosimilar TNF inhibitors are expected to enhance treatment accessibility. However, the market still faces challenges, including high treatment costs and potential side effects
- North America currently dominates the market, but Asia-Pacific is anticipated to witness the fastest growth due to rising healthcare awareness and increasing incidence of liver-related disorders
